Conference Reports for NATAP

Back

43rd ICAAC Meeting   Chicago, Sept 13-17, 2003     Anti-Hepatitis B Virus (HBV) Activity of Tenofovir Disoproxil Fumarate (TDF) in Human Immunodeficiency Virus (HIV) Co-Infected Patients - (10/6/03)   Evaluation of Computed Tomography and Ultrasonography for Assessment of Facial Fat in HIV-Infected Patients - (9/29/03)   ICAAC Summary Report - Written by David Margolis, MD, University of Texas, Southwestern Medical Center and Dallas VA Medical Center - (9/24/03)   Two Year Analysis of Stavudine Extended-Release/Prolonged Release Capsules (XR/PRC) as Compared to Stavudine Immediate-Release (IR): Efficacy and Safety - Written by Judith Aberg, MD, Washington University, St Louis, Missouri - (9/23/03)   Saquinavir/Ritonavir (Sqv/R) Pharmacokinetics (Pks) In HIV+ Subjects: 1000/100 Mg Bid VS 1600/100 and 2000/100 Mg Once Daily (OD) - (9/23/03)   Genetics and Virologic, Biochemical & Histologic Response to Pegylated Interferon and Ribavirin in HIV/HCV Co-infected Individuals - (9/22/03)   D4T Once Daily 2-Year Follow-up: lipoatrophy and peripheral neuropathy, and antiviral activity - (9/22/03)   PK Drug Interaction and Safety of Tenofovir and Kaletra - (9/22/03)   Kaletra (Lopinavir/ritonavir) in Antiretroviral-Naive HIV-Infected Patients: 5-Year Follow-Up - (9/22/03)   Dyslipidemia Improvement in Patients Switching from D4T to Tenofovir - Written by Judith Aberg, MD, Washington University, St louis, Missouri and the ACTG - (9/22/03)   PK of Once daily Reyataz, DDI-EC, Tenofovir - (9/22/03)   Switch from PI to Nevirapine: 3 yr follow-up, lipids, viral load - (9/19/03)   Tenofovir and Norgestimate/Ethinyl Estradiol: lack of a pharmacokinetic drug interaction - (9/19/03)   PK Drug Interaction and Safety of Tenofovir and Kaletra - (9/19/03)   Similar 96-wk Renal Safety Profile of Tenofovir vs d4T: used in combination with 3TC/efavirenz in treatment-naïve patients - (9/19/03)   Kaletra - Fosamprenavir Interaction Study - (9/18/03)   Effects of High-Dose Vitamin C on the Steady State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers - (9/18/03)   Viral Failure to Tenofovir/Abacavir/3TC - (9/18/03)   Dyslipidemia Improvement After Switch From d4T to Tenofovir - (9/18/03)   Pilot Study of the Safety and Efficacy of Kaletra as Single Drug HAART in HIV+ ART Naïve Patients: interim analysis of subjects completing at least 24 weeks of a 48 week study - (9/17/03)   The Efficacy of Lopinavir in Individuals Experiencing Protease Inhibitor Failure - (9/17/03)   Abacavir Once Daily Study - (9/17/03)   CCR5 Chemokine Receptor blocker: first report of anti-HIV effect in HIV-infected people - Written by David Margolis, MD, University of Texas Southwestern Medical Center, Dallas VA Med Ctr - (9/16/03)   D4T Once Daily 2-Year Follow-up: lipoatrophy and peripheral neuropathy, and antiviral activity - (9/16/03)   DDI in Treatment Experienced HIV-infected Patients - (9/15/03)   UK-427,857 (HIV attachment inhibitor) - (9/15/03)